Chemo-enzymatic cascade processes are invaluable due to their ability to rapidly construct high-value products from available feedstock chemicals in a one-pot relay manner. In a patent, 214894-89-0, name is 5-(Bromomethyl)-2,3-dihydro-1,4-benzodioxine, introducing its new discovery. Quality Control of 5-(Bromomethyl)-2,3-dihydro-1,4-benzodioxine
In this study, 22 new betulinic acid (BA) derivatives were synthesized and tested for their inhibition of the chymotrypsin-like activity of 20S proteasome. From the SAR study, we concluded that the C-3 and C-30 positions are the pharmacophores for increasing the proteasome inhibition effects, and larger lipophilic or aromatic side chains are favored at these positions. Among the BA derivatives tested, compounds 13, 20, and 21 showed the best proteasome inhibition activity with IC50 values of 1.42, 1.56, and 1.80 muM, respectively, which are three to fourfold more potent than the proteasome inhibition controls LLM-F and lactacystin.
One of the oldest and most widely used commercial enzyme inhibitors is aspirin, Quality Control of 5-(Bromomethyl)-2,3-dihydro-1,4-benzodioxine, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 214894-89-0